CRBP logo

CORBUS PHARMACEUTICALS HOLDI

CRBPNASDAQ
🏆 #3966 by market capEarnings Nov 10US Equity
$934.74▼ $64.68 (−6.92%)
Simulated price
🔔
Track CRBP
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 6.9%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$128M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
40
Weak
No chart data available for CRBP.

Trading Snapshot

Day Range
$922.46 – $940.51
52-Week Range
$6.33 – $20.56
Volume
$4.04B
Avg Volume
$3.76B
Shares Outstanding
18.5M
Next Earnings
Nov 29, 2026

Fundamentals Snapshot

Annual Revenue
$9M
Last Q Revenue
$2M
P/E Ratio
-1.1
P/S Ratio
0.0x
EPS (TTM)
$-5.25
Dividend Yield
0.00%
Dilution (1yr)
+9.3%

Why Investors Own CRBP

  • ✓High-growth profile — revenue up -8.4% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 40% gross margin and 5% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CRBP logo

CORBUS PHARMACEUTICALS HOLDI

CRBP
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$85M▲ +75.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$64M▲ +54.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
13.3M▲ +9.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$27M▲ +$13M YoY
StockOtter · stockotter.space

About CORBUS PHARMACEUTICALS HOLDI

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
40/100

Analyst Price Target

ⓘ
Average Target
$1,024.35
▲ +9.6% Upside
High Target$1,177.59
Low Target$797.95
Based on 31 analysts

Latest News & Updates

🚀
CNBC·2h ago

CORBUS PHARMACEUTICALS HOLDI tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift CRBP price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

CORBUS PHARMACEUTICALS HOLDI announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.